Evidence map›Paper›PMID 30672363›Full record

ArticleJournal of the International Association of Providers of AIDS Care

Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults.

Oche O Agbaji, Isaac O Abah, Augustine O Ebonyi, Zumnan M Gimba, Esla E Abene, Simji S Gomerep, Kakjing D Falang, Joseph Anejo-Okopi, Patricia A Agaba, Placid O Ugoagwu and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the International Association of Providers of AIDS Care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Tenofovir disoproxil fumarate mediates neuronal injury by inducing neurotoxicity.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023
    Article
  4. Review
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Oche O Agbaji1 Department of Medicine, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
Isaac O Abah2 APIN-supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria.ORCID 0000-0003-1977-5570
Augustine O Ebonyi2 APIN-supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria.
Zumnan M Gimba1 Department of Medicine, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
Esla E Abene1 Department of Medicine, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
Simji S Gomerep1 Department of Medicine, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
Kakjing D Falang2 APIN-supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria.
Joseph Anejo-Okopi2 APIN-supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria.
Patricia A Agaba2 APIN-supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria.
Placid O Ugoagwu2 APIN-supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria.
Emmanuel I Agaba1 Department of Medicine, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
Godwin E Imade2 APIN-supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria.
Atiene S Sagay2 APIN-supported HIV Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria.
Prosper Okonkwo9 APIN Public Health Initiatives, Ltd/Gte, Abuja, Nigeria.
John A Idoko1 Department of Medicine, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
Phyllis J Kanki10 Department of Immunology & Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
University of Jos · NGJos University Teaching Hospital · NGAIDS Prevention Initiative in Nigeria · NGHarvard University · US

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
Support of Training and Mentoring in Nigeria for Academics (STAMINA)D43TW010130 · FIC · UNIVERSITY OF JOS · PI SAGAY, ATIENE SOLOMON · 2015 to 2019
$3.2M
FIC NIH HHS D43 TW010130FIC NIH HHS D43 TW010543
6 · The paper itself

Abstract

OBJECTIVES AND

methodThere are growing concerns of tenofovir disoproxil fumarate (TDF)-associated renal toxicity. We evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015. Multivariate logistic regression was used to identify predictors of renal impairment at different time over 144 weeks of antiretroviral therapy (ART).

resultsData of 4897 patients, median age 42 years (interquartile range: 36-49), and 61% females were analyzed. The prevalence of renal impairment increased from 10% at week 24 to 45% at 144 weeks in TDF-exposed participants compared to an increase from 8% at 24 weeks to 14% at 144 weeks in TDF-unexposed participants. Tenofovir disoproxil fumarate exposure predicted the risk of renal impairment at 144 weeks of ART (odds ratio: 2.36; 95% confidence interval: 1.28-4.34).

conclusionLong-term exposure to TDF-based ART significantly increases the likelihood of renal impairment. The continued use of TDF-based regimen in our setting should be reviewed. We recommend the urgent introduction of tenofovir alafenamide-based regimen in the HIV treatment guidelines of Nigeria and other resource-limited countries.

Indexed as

AdultAnti-HIV AgentsFemaleGlomerular Filtration RateHIV InfectionsHumansMaleMiddle AgedNigeriaProspective StudiesRenal InsufficiencyRetrospective StudiesTenofovirAnti-HIV AgentsTenofovirARTHIVNigeriarenal impairmenttenofovir

Identifiers

PMID30672363
PMCPMC6546287
OpenAlexW2913784398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.